Senti Biosciences Inc. Common Stock SNTI · Stock Open Senti Biosciences Inc. Common Stock in new tab
Senti Biosciences Inc. Common Stock Analysis (SNTI)
Is Senti Biosciences Inc. Common Stock a good investment? Senti Biosciences Inc. Common Stock (SNTI) is currently trading at 0.3701 USD. Market analysts have a consensus price target of 13.00 USD. This suggests a potential upside from current levels.
In terms of valuation, the stock trades at a P/E ratio of 4.54. This relatively low multiple may signal that Senti Biosciences Inc. Common Stock is undervalued compared to historical market norms.
Earnings Schedule: Senti Biosciences Inc. Common Stock is expected to release its next earnings report on Aug. 6, 2026. The market consensus estimate for Forward EPS is -0.95.
Investor FAQ
Does Senti Biosciences Inc. Common Stock pay a dividend?
No, it does not currently pay a dividend.
What asset class is Senti Biosciences Inc. Common Stock?
Senti Biosciences Inc. Common Stock is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Aug. 6, 2026. The company currently has a trailing EPS of -1.46.
Company Profile
Senti Biosciences Holdings, Inc., a clinical stage biotechnology company, develops cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The company's lead product candidates utilize off-the-shelf healthy adult donor derived natural killer (NK) cells to create CAR-NK cells outfitted with gene circuit technologies in various oncology indications with unmet need. It offers SENTI-202, a logic gated off-the-shelf CAR-NK cell therapy for the treatment of blood cancers and relapsed/refractory hematological malignancies, including acute myeloid leukemia. In addition, the company develops the tumor-associated antigen and protective antigen paired discovery platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. Further, its pipeline includes preclinical programs, which comprise a solid tumor cell therapy program; and partnered programs related to cell therapies for regenerative medicines. The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd. The company was formerly known as Senti Biosciences, Inc. and changed its name to Senti Biosciences Holdings, Inc. in April 2026. The company was incorporated in 2016 and is headquartered in South San Francisco, California.
| Split Date | Split Ratio to 1 |
|---|---|
| July 18, 2024 | 0.100000 |
Community Discussion